Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Clinical trial NCT02895360 · COMPLETED
Trial details
- NCT number
- NCT02895360
- Sponsor
- Basilea Pharmaceutica
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-24
- Primary completion
- 2020-08-07
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.